Charles C. Wykoff, MD, PhD

Associate Professor of Clinical Ophthalmology, Institute for Academic Medicine
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Charles Wykoff, MD, PhD, graduated Phi Beta Kappa from MIT, received his PhD from Oxford University in England while on a Marshall Scholarship, and his MD from Harvard Medical School. As a medical student he co-authored the book Fighting Global Blindness. While pursuing vitreoretinal training at Bascom Palmer Eye Institute he was awarded a Heed Fellowship, the Ronald G. Michels Fellowship Award, and served as Chief Resident/Co-Director of Ocular Trauma.

Dr. Wykoff has extensive expertise in clinical trial design and coordination. His research interests pertain to angiogenesis and retinal vascular diseases including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgery topics such as retinal detachment and macular surgery. Dr. Wykoff has written and published over 120 peer-reviewed scientific manuscripts, book chapters, national meeting presentations and abstracts. Dr. Wykoff is Director of the Retina Consultants of Houston and Houston Methodist Hospital joint Argus II retinal prosthetic program – the only Gulf Coast site approved for surgical implantation of this unique technology for patients blind from retinitis pigmentosa. Dr. Wykoff is Co-Director of the Greater Houston Retina Research Foundation, was awarded the American Academy of Ophthalmology Achievement Award in 2015 and is an elected member of the Retina Society and the Macula Society. He also serves as the Academic Program Director for the Vit-buckle Society Annual Meeting, and is a member of the AAO, ARVO, ASRS and FACS.

Areas Of Expertise

Retina Diabetic retinopathy Macular degeneration Vitreoretinal surgery
Education & Training

Internship, Harvard University
MD, Harvard University
Clinical Fellowship, Bascom Palmer Eye Inst & Hosp
Residency, Bascom Palmer Eye Inst & Hosp

Distribution of Nonperfusion and Neovascularization on Ultrawide-Field Fluorescein Angiography in Proliferative Diabetic Retinopathy (RECOVERY Study): Report 1
Fan, W, Nittala, MG, Velaga, SB, Hirano, T, Wykoff, CC, Ip, M, Lampen, SIR, van Hemert, J, Fleming, A, Verhoek, M & Sadda, SVR 2019, American Journal of Ophthalmology, vol. 206, pp. 154-160.

Office-based intravitreal injection of expansile gas for management of macular hole in previously vitrectomized eyes
Apolinario, MA, Lampen, SIR, Wong, TP, Henry, CR & Wykoff, CC 2019, American Journal of Ophthalmology Case Reports, vol. 15, 100492.

Real-World Trends in Intravitreal Injection Practices among American Retina Specialists
Chaturvedi, R, Wannamaker, KW, Riviere, PJ, Khanani, AM, Wykoff, CC & Chao, DL 2019, Ophthalmology Retina, vol. 3, no. 8, pp. 656-662.

Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes
TREX-DME Study Group 2019, American Journal of Ophthalmology, vol. 202, pp. 91-99.

Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration
Lynch, SK, Lee, K, Chen, Z, Folk, JC, Schmidt-Erfurth, U, Gerendas, BS, Wahle, A, Wykoff, CC & Abràmoff, MD 2019, Investigative ophthalmology & visual science, vol. 60, no. 6, pp. 2134-2139.

Re: Adrean et al.: Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol (Ophthalmology. 2018;125:1047-1053)
Wykoff, CC, Rusakevich, AM & Moshfeghi, DM 2019, Ophthalmology, vol. 126, no. 3, pp. e18-e19.

Fovea-sparing rhegmatogenous retinal detachments: impact of clinical factors including time to surgery on visual and anatomic outcomes
Lee, IT, Lampen, SIR, Wong, TP, Major, JC & Wykoff, CC 2019, Graefes Archive for Clinical and Experimental Ophthalmology.

Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach
Habot-Wilner, Z, Noronha, G & Wykoff, CC 2019, Acta Ophthalmologica.

Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study
Wykoff, CC, Shah, C, Dhoot, D, Coleman, HR, Thompson, D, Du, W, Baker, K, Vitti, R, Berliner, AJ, Metzig, C & Saroj, N 2019, Ophthalmology.

Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2
The MacTel Study Group 2019, Acta Ophthalmologica.

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial
Sahni, J, Patel, SS, Dugel, PU, Khanani, AM, Jhaveri, CD, Wykoff, CC, Hershberger, VS, Pauly-Evers, M, Sadikhov, S, Szczesny, P, Schwab, D, Nogoceke, E, Osborne, A, Weikert, R & Fauser, S 2019, Ophthalmology.

Innovation in neovascular age-related macular degeneration: Consideration of brolucizumab, abicipar, and the port delivery system
Wykoff, CC, Hariprasad, SM & Zhou, B 2018, Ophthalmic Surgery Lasers and Imaging Retina, vol. 49, no. 12, pp. 913-917.

Suprachoroidal space alterations following delivery of triamcinolone acetonide: Post-hoc analysis of the phase 1/2 HULK study of patients with diabetic macular edema
Lampen, SIR, Khurana, RN, Noronha, G, Brown, DM & Wykoff, CC 2018, Ophthalmic Surgery Lasers and Imaging Retina, vol. 49, no. 9, pp. 692-697.

Predictors of visual acuity outcomes following vitrectomy for idiopathic macular hole
Amram, AL, Mandviwala, MM, Ou, WC, Wykoff, CC & Shah, AR 2018, Ophthalmic Surgery Lasers and Imaging Retina, vol. 49, no. 8, pp. 566-570.

Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial
TREX-AMD Study Group 2018, American Journal of Ophthalmology, vol. 192, pp. 84-90.

Ultra-wide-field fluorescein angiography–guided normalization of ischemic index calculation in eyes with retinal vein occlusion
Wang, K, Falavarjani, KG, Nittala, MG, Sagong, M, Wykoff, CC, van Hemert, J, Ip, M & Sadda, SR 2018, Investigative Ophthalmology and Visual Science, vol. 59, no. 8, pp. 3278-3285.

When and How to Incorporate Steroids for Persistent Diabetic Macular Edema: A Discussion of Real-World Treatment Optimization Strategies
Eichenbaum, DA, Buznego, C, Weng, CY, Dhoot, DS, Wykoff, CC & Sheth, VS 2018, Ophthalmic surgery, lasers & imaging retina, vol. 49, no. 7, pp. S5-S15.

Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema
Payne, JF, Clark, WL, Bruce, BB, Wykoff, CC, Brown, DM, Menke, BM, Iverson, SM, Allen, KF, Boyer, DS & Treat & Extend Protocol in Patients with Diabetic Macular Edema Study Group 2018, Ophthalmology.

Five-year outcomes of surgically treated symptomatic epiretinal membranes with and without internal limiting membrane peeling
Sultan, H, Wykoff, CC & Shah, AR 2018, Ophthalmic Surgery Lasers and Imaging Retina, vol. 49, no. 5, pp. 296-302.

Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study
Wykoff, CC, Ou, WC, Khurana, RN, Brown, DM, Lloyd Clark, W & Boyer, DS 2018, British Journal of Ophthalmology, vol. 102, no. 5, pp. 631-636.

Live Chat Available